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| INTRODUCTION
Oral immunotherapy (OIT) has been used in research settings for the past decade and is now being evaluated in a Phase III clinical trial in subjects with peanut allergy. Subjects with peanut, milk and egg allergies have been successfully desensitized with OIT to the offending allergen in several landmark studies. [1] [2] [3] [4] [5] [6] Importantly, a large range of OIT doses have been used as maintenance therapy. 7 In the case of peanut OIT, one study demonstrated that as little as 300 mg was effective for desensitization, 8 whereas others have used 800, 1 1800, 3 2000 9 and 4000 mg 5 maintenance doses. While OIT protocols were initially being developed and implemented, the consensus was that higher maintenance doses would cause robust desensitization and may lead to long-term sustained unresponsiveness (SU)
after therapy was stopped. However, SU is not readily induced in the majority of subjects on peanut OIT, 6 or those on egg and milk OIT, 2,4 even after several years on maintenance therapy at doses into the hundreds or thousands of milligrams of protein per day.
The underlying mechanisms of OIT have not been fully elucidated, although some immunologic changes have been shown across trials. Effector cell suppression has been demonstrated in OIT studies for peanut, milk and egg OIT. 2, 3, 5, 10 Within 6-12 months of initiating OIT, mast cell reactivity as measured by skin prick testing is decreased and basophils become hyporesponsive to ex vivo antigen stimulation. 3, 11 Peanut-specific IgE levels in serum often increase during the build-up phase of OIT then later decrease below baseline levels, typically after greater than 12 months of therapy. 5, 6 Peanutspecific IgG and IgG4 increase within the first 3 months of therapy and stay elevated with ongoing daily exposure to antigen. 3, 5, 6 Changes in T cells have also been shown during OIT, with increases in Tregs and decreases in Th2-type cytokine-secreting T cells. 3, 5, 12, 13 There are suggestions that the pathogenic peanut-specific Th2 cells become anergic or are depleted during OIT, 14 although residual Th2 effector cells have been found following OIT, 13 and it remains unclear whether pathogenic Th2 cells re-emerge once therapy is stopped. One study demonstrated that cellular changes induced by peanut OIT are often transient, 15 which seem to reflect the return of clinical symptoms during oral food challenge (OFC) after OIT has been stopped. 16 While it is clear that OIT modulates the immune response to peanut allergens, there are no studies showing how these changes are impacted by the amount of antigen consumed as daily maintenance therapy.
The first trial of peanut OIT conducted exclusively in preschool age children aged 9-36 months with new-onset peanut allergy was recently reported by our group. 8 We demonstrated the highest rate of SU to-date at 78%. This trial was highly innovative in that it captured young children, presumably with a more malleable immune response to peanut that could be altered with OIT. Importantly, this is the first trial to directly compare two doses of peanut OIT, with a low dose of 300 mg and a high dose of 3000 mg. In addition to the clinical outcomes reported, 8 we investigated the immune responses during OIT from sequential blood draws throughout the trial. The aims of the immunologic studies were to determine how OIT modulates the immune response to peanut and to determine whether there were differences between groups of subjects receiving high-or low-dose maintenance therapy. Here, we report our findings on changes in the peanut-induced cytokine production, Treg numbers, peanut-responsive CD4+ T cells, and basophil reactivity and compare these outcomes between groups. The salient points of interest for the immunologic studies are as follows: Dosing was double-blinded; subjects entered the trial and began peanut OIT at a dose of 0.1 mg, then underwent build-up to 300 mg of peanut protein daily; upon reaching 300 mg peanut daily
| METHODS

| Clinical trial
(at approximately 11-12 months on the OIT protocol), subjects randomized to high dose continued escalating to 3000 mg of peanut protein, while subjects randomized to low dose continued to receive more flour product, with the active peanut content held steady at 300 mg and eventually the placebo filler (oat flour) reached 2700 mg. A total of 49 subjects were consented and enrolled in the trial. An ELISA kit (Biolegend, San Diego, CA, USA) was used to quantify human IL-9.
| Blood samples
| CFSE assay
Peripheral blood mononuclear cells were stained with CFSE using 
| IgE-stripped basophil assay
To assess the ability of plasma from subjects at various time-points throughout the OIT protocol to activate basophils, we used an IgEstripping assay. 17 Healthy donor blood was used as a source of PBMCs, then stripped of IgE with 10 mmol/L lactic acid, 0.14 mol/L NaCl, 5 mmol/L KCl at pH 3.9 for 10 minutes on ice. Cells were washed, 1 million PBMCs were resuspended in 200 μL of RPMI (per test condition) and then primed with 200 μL of plasma from OIT subjects at 0, 12, 24 and 36 months in a 37°C CO 2 incubator for 1 hour.
Stimulations were conducted with 0.1 μg/mL peanut protein extract for 30 minutes in a 37°C CO 2 incubator. Basophil activation was assessed as described above. Unstimulated activation was subtracted from the peanut-stimulated values and is reported here.
| Peanut-specific IgG4/IgE ratio
Peanut-specific IgE (in kU/L) and IgG4 (in mg/L) were quantified on an ImmunoCAP100 instrument as previously reported. 5 Ratios were calculated by first converting both IgG4 and IgE into μg/L then dividing peanut-specific IgG4 quantities by peanut-specific IgE quantities.
A conversion factor of 2.42 μg/L = 1 kU/L was used for IgE.
| Statistical analysis
For the longitudinal analysis of immune responses, the immune response variables were log-transformed (represented as natural logarithm, ln) and regressed against time (in months) using generalized additive mixed model (GAMM). 18 B-splines functions were used for fitting the GAMM. The analysis was performed for each outcome and each dosage group separately using R (www.r-project.org) version 
| Peanut OIT suppresses Th2-, Th9-, Th1-and
Tr1-type cytokines without differences between highand low-dose OIT groups
Longitudinal analysis of PBMC cytokine production in response to peanut stimulation was monitored for subjects throughout the course of OIT. The pro-allergic, Th2-type cytokines IL-13 and IL-5
were both significantly decreased from baseline throughout the OIT protocol ( Figures 2 and S1 ), but there were no differences between subjects receiving 300 mg or 3000 mg of peanut OIT. IL-9, a mast cell growth factor and cytokine that enhances IgE production from B cells, was also significantly decreased throughout the course of OIT.
As with the Th2-type cytokines, no differences between high-or low-dose OIT groups were detected for IL-9 secretion. These findings indicate that OIT modulates the pro-allergic cytokine production from T cells, and there is no apparent difference whether the subject ingested high-or low-dose peanut protein OIT as maintenance. Of note, IL-4 and IL-12p70 were not detectable and are thus not shown or discussed further.
Additional cytokines were quantified to determine effects of OIT on potential skewing of the immune response (Figures 3 and S1 ).
Somewhat surprisingly, we measured significant decreases in IL-10, TNF-α and IFN-ɣ in both the high-and low-dose groups. As with the Th2 cytokines, there were no differences detected between the groups. IL-17 secretion was decreased in the low-dose OIT group but not the high-dose group, although no significant difference was found when comparing the two groups. These data indicate an absence of immunologic skewing caused by peanut OIT and instead show a decrease in important Th1 and regulatory cytokines.
| Cytokines secreted from PBMCs stimulated with egg antigen are modestly modulated during peanut OIT
Egg stimulation of PBMCs was carried out at the same time-points described above for peanut stimulation. Interestingly, some of the cytokines induced by egg stimulation were reduced during peanut OIT ( Figure 4 ). For example, IL-13 was decreased (P < 0.05) in both high-and low-dose groups, although the slope was only approximately half that with peanut stimulation. TNF-α production resulting from egg stimulation was also decreased in both groups. Other cytokines were either decreased during OIT in only one of the groups or were not significantly altered. There were no differences in cytokine production between the high-and low-dose groups. Peanut-induced Tregs were also assessed over the course of OIT. We found a small, but statistically significant increase from baseline at 4 months on OIT while all subjects were in the build-up phase and on the same dose of OIT ( Figure 5C ), which was not sustained over the course of therapy ( Figure 5D ). Figure 5D shows Treg responses for high-and low-dose groups, neither demonstrate a significant change from baseline over the course of the OIT protocol.
Importantly, there is no difference between the groups in terms of
Treg numbers induced by peanut stimulation during OIT.
| Basophil suppression in response to peanut allergens is not different between high-and low-dose OIT groups
Basophil reactivity in response to peanut antigen stimulation was measured longitudinally by stripping IgE from healthy donor basophils and priming with plasma from subjects at annual visits. Limited plasma volumes restricted testing in this assay to n = 6 high-dose and n = 9 low-dose OIT subjects. Nevertheless, significant suppression was found at 12, 24 and 36 months compared to baseline reactivity and there was no difference between high-and low-dose OIT groups ( Figure 6A ). These findings indicate that subjects' peanut-IgE following OIT was not cross-linked as efficiently as at baseline. This could be due to a shift in the balance of peanut IgG4/IgE ratio, which significantly increased in both groups ( Figure 6B ).
Whole blood basophil activation assays were conducted at the time of desensitization and SU oral food challenges ( Figure 7) . A total of 23 subjects (n = 13 high dose and n = 10 low dose) had blood collected at both oral food challenges and were included in the analysis. These assays indicate highly suppressed basophil reactivity to peanut as all four doses used in the assay had medians <5% CD63+ basophils. There were no increases in either group in terms of reactivity during the 4 weeks off of OIT (ie between DS and SU OFC). Importantly, there was no difference in terms of basophil reactivity at the DS or SU challenge at any of the four doses when comparing the high-and low-dose OIT groups. These findings indicate that OIT suppressed basophil reactivity, which did not return during a 4-week period without peanut dosing and that high-and low-dose maintenance had equivalent effects on suppression of the basophil response to peanut.
| DISCUSSION
Oral immunotherapy is a promising approach to desensitize food allergic individuals and has demonstrated efficacy for several major food allergies, including peanut, milk and egg. However, key knowledge gaps remain, including optimal dose selection, immunologic OIT has not been demonstrated before and may be especially important as two reports have found that IL-9 differentiates peanut-sensitized and peanut-allergic individuals. 21, 22 Thus, decreasing IL-9 with
OIT could possibly restore a state of tolerance. We did not find any evidence of increased Th1-type or Tr1-type cytokines that would suggest a skewing away from Th2-driven responses to peanut.
Instead, we found decreases in IL-10, TNF-α and IFN-ɣ. Looking at the immune cytokine profiles of egg responses, there is a clear Th1
and Tr1 favoured profile compared to peanut in these subjects (Figure 1) . We postulate that OIT thus does not restore a state of "natural" tolerance like is seen for egg in these subjects, but instead OIT leads to an "induced" state of tolerance characterized by low cytokine production in response to peanut stimulation.
It is unclear what mechanisms are involved in the T cell compartment that ultimately lead to SU. Several mechanisms, such as anergy, deletion and/or exhaustion, could cause decreased antigen-responsive cell numbers leading to decreased cytokine production. 23 The One of the limitations of our study is that we did not perform assays for Treg subsets, FoxP3 methylation or Treg function that may be more closely tied to tolerance. 12 Additionally, the early increase in peanut-responsive cells during build-up may be important for driving showed the emergence of an anergic T cell population during peanut OIT, and this will be interesting to investigate further in larger studies.
14 Regardless of which cellular mechanisms lead to tolerance, our study demonstrates that even with a 10-fold difference in maintenance dose, similar changes in the T cell cytokine profiles emerge, dramatically suppressing cytokine production in response to peanut antigens.
Oral immunotherapy clearly leads to suppression of basophil responses to allergens while continuing to take doses. 3, 5, 11, 16 Here, we demonstrated that plasma from subjects on OIT leads to lower basophil reactivity and is likely linked to the balance between peanut-IgG4 and IgE. Additionally, in whole blood assays we found low median levels of basophil reactivity at time of desensitization OFC while subjects were taking vastly different maintenance doses. While it is still unclear if decreased IgE combined with increased IgG4, or some other mechanism is causing these suppressive effects, we have
shown that a high-and low-dose maintenance therapy yields similar outcomes in terms of suppressing basophil reactivity. Importantly, the basophil reactivity in this cohort of preschool age children did not return after 4 weeks avoidance following the OIT protocol at the SU OFC, unlike the finding in another OIT study, which enrolled older children. 16 The findings here of low basophil reactivity and a high rate of SU appear to indicate that basophil reactivity may reflect clinical outcomes of SU.
Clinically, the low-dose OIT maintenance therapy in this preschool age cohort was sufficient in most subjects to prevent allergic symptoms during a 5000 mg peanut protein OFC at the end of treatment and again 1 month after stopping treatment. 8 Findings in the present work indicate that low-dose OIT may serve as a method to drive down Th2 cytokines, peanut-specific IgE and basophil reactivity, while increasing IgG4 and Tregs leading to long-term "correction" of the aberrant allergic response to peanut. Key drivers of SU may be reduction in Th2 and IL-9 responses and increased IgG4/IgE ratio. While these have been demonstrated in other trials with older children, it did not always result in SU, hinting that the younger age group may be more amenable to treatment. Interestingly, in the LEAP trial, which examined early exposure to peanut as a prevention approach, the elevated peanut-specific IgG4 response, but not a decrease in peanutspecific IgE, was found to associate with prevention of peanut allergy. 25 It appears that OIT may work by boosting the peanut-IgG4
as happens with regular exposure in oral tolerance induction in LEAP, while also driving down the peanut-IgE response, which was not seen in LEAP. This restoration of a balance between IgG4 and IgE following OIT may ultimately lead to SU in young children. give additional insight into how OIT changed the peanut-specific T cell phenotypes in these young children. Missing baseline samples from the whole blood basophil activation assay also present a limitation. While we acknowledge the limitations of our study, we have laid important groundwork to be addressed in future clinical and mechanistic studies that will lead to better understanding of how OIT modulates the immune response to peanut.
Future directions based on these data would be to conduct dose-finding trials. Since a 10-fold difference in maintenance OIT doses produces the same results clinically and immunologically, one must wonder what the lowest threshold would be, assuming therapy with less than 300 mg would be clinically effective. Another critical question to address is how long these cellular changes, and clinical benefit persist after OIT. An ongoing trial (clinical trials # NCT01867671) will address this question as subjects will undergo OIT then stop dosing for 6 months. It is possible that in these young children with newly diagnosed peanut allergy, we may have induced a very long-lived change in immunologic parameters along with protection from ingestion of peanut allergens. Ultimately, it will be important to relate the changes in immunologic responses to clinical outcomes in future studies with larger numbers of subjects.
In conclusion, we have demonstrated that OIT modulates key pro-allergic immune compartments, namely T cells and basophils, along with changes in peanut-IgG4 and IgE. The most striking finding from this study is that high-and low-dose OIT lead to similar changes in these compartments.
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